logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
2/4/2021 8:08:59 AM Alexion Q4 Total Revenues $1.59 Bln, 15% Increase From Last Year
11/20/2020 2:24:49 AM Alexion: EC Approves New 100 Mg/mL Intravenous Formulation Of ULTOMIRIS Or Ravulizumab
10/29/2020 6:42:25 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its FY20 EPS Estimate To 11.70 - 12.00 From 10.65 - 10.95
10/29/2020 6:41:53 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its FY20 Revenue Estimate To $5,900 to $5,950 Mln From $5,550 to $5,600 Mln
10/29/2020 6:34:21 AM Alexion Q3 GAAP EPS $2.62 Vs $2.08 Last Year
10/12/2020 8:34:14 AM Alexion Gets FDA Approval For New Advanced Formulation Of ULTOMIRIS With Significantly Reduced Infusion Time
10/6/2020 6:39:25 AM Alexion Pharma Sees 2025 Global Revenue Target Of $9 To $10 Bln; To Will Highlight Strategic Advancements